Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial

Area of Science:

• Cardiology
• Pharmacology
• Inflammation Research

Background:

• Inflammation is central to acute coronary syndromes (ACS).
• Colchicine, an anti-inflammatory gout medication, is explored for cardiovascular benefits.
• Investigating colchicine's efficacy in ACS patients is warranted.

Purpose of the Study:

• To evaluate the effectiveness of colchicine in patients with acute coronary syndromes.
• To assess colchicine's impact on cardiovascular outcomes and mortality in ACS.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled trial.
• 795 adult patients with ACS received colchicine or placebo for 12 months.
• Primary outcome: composite of mortality, ACS events, urgent revascularization, or ischemic stroke.

Main Results:

• Colchicine did not significantly reduce the primary composite outcome (P=0.09).
• A higher rate of total mortality was observed in the colchicine group (8 vs. 1, P=0.017).
• Noncardiovascular deaths were notably higher in the colchicine group (5 vs. 0, P=0.024).

Conclusions:

• Colchicine addition to standard therapy did not improve 12-month cardiovascular outcomes in ACS patients.
• Colchicine use in ACS was associated with an increased mortality rate.
• Further research is needed to clarify colchicine's role in cardiovascular medicine.